Thrombophilic state in young patients with acute myocardial infarction

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 4, 2015, Pages 474-480

  Maor, Elad ^a   Fefer, Paul ^a   Varon, David ^c   Rosenberg, Nurit ^a,b   Levi, Nitza ^a   Hod, Hanoch ^a,b   Matetzky, Shlomi ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Antiphospholipid antibody syndrome; Cardiovascular disease; Thrombosis

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOOD; COMPLICATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOLOGY; PROSPECTIVE STUDY; THROMBOPHILIA;

ACUTE CORONARY SYNDROME; ADULT; ANTIPHOSPHOLIPID SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; THROMBOPHILIA;

EID: 84939944850     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1166-2     Document Type: Article

References (34)

1. Doughty M, Mehta R, Bruckman D, Das S, Karavite D, Tsai T, Eagle K (2002) Acute myocardial infarction in the young—the University of Michigan experience. Am Heart J 143(1):56–62
2. Zimmerman FH, Cameron A, Fisher LD, Grace N (1995) Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (coronary artery surgery study registry). J Am Coll Cardiol 26(3):654–661
3. Pineda J, Marín F, Marco P, Roldán V, Valencia J, Ruiz-Nodar JM, Sogorb F, Lip GYH (2009) Premature coronary artery disease in young (age < 45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol 136(2):222–225
4. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U (1994) Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330(15):1041–1046
5. Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, Dardik R, Baron Z, Seligsohn U (1999) Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 93(7):2186–2190
6. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette J-C et al (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an International Workshop. Arthritis Rheum 42(7):1309–1311
7. Levine JS, Branch DW, Rauch J (2002) The antiphospholipid syndrome. New Engl J Med 346(10):752–763
8. Cortellaro M, Boschetti C, Cardillo M, Barbui T (1992) Antiphospholipid antibodies in patients with previous myocardial infarction. Lancet 339:929–930
9. Hamsten A, Björkholm M, Norberg R, De Faire U, Holm G (1986) Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 327:113–116
10. Zuckerman E, Toubi E, Shiran A, Sabo E, Shmuel Z, Golan TD, Abinader E, Yeshurun D (1996) Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study. Am J Med 101(4):381–386
11. Fless GM, Rolih CA, Scanu AM (1984) Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol Chem 259(18):11470–11478
12. Loscalzo J (1990) Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arterioscler Thromb Vasc Biol 10(5):672–679
13. Tabas I, Li Y, Brocia RW, Xu SW, Swenson TL, Williams KJ (1993) Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation. J Biol Chem 268(27):20419–20432
14. Aznar J, Estellés A, Bretó M, España F (1993) Euglobulin clot lysis induced by tissue type plasminogen activator in subjects with increased levels and different isoforms of lipoprotein (a). Thromb Res 72(5):459–465
15. Scanu AM (1993) Structural basis for the presumptive atherothrombogenic action of lipoprotein(a). Facts and speculations. Biochem Pharmacol 46(10):1675–1680
16. Yamazaki M, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I et al (1994) Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome. Thromb Haemost 71(4):424–427
17. Vaarala O (1998) Antiphospholipid antibodies and myocardial infarction. Lupus Suppl 2:S132–S134
18. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T (1995) Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91(1):23–27
19. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM (2003) Premature coronary artery atherosclerosis in systemic lupus erythematosus. New Engl J Med 349(25):2407–2415
20. Roman MJ, Shanker B-A, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. New Engl J Med 349(25):2399–2406
21. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, Jara LJ, Abu Shakra M, Meroni PL, Sherer Y (2005) Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112(21):3337–3347
22. Shoenfeld Y, Sherer Y, Harats D (2001) Atherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol 22(6):293–295
23. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB (2005) Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. New Engl J Med 353(1):46–57
24. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM (1992) Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 360(6405):670–672
25. Takami S, Yamashita S, Kihara S, Ishigami M, Takemura K, Kume N, Kita T, Matsuzawa Y (1998) Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 97(8):721–728
26. Poon M, Zhang X, Dunsky K, Taubman MB, Harpel PC (1997) Apolipoprotein(a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity. Clin Genet 52(5):308–313
27. Haque NS, Zhang X, French DL, Li J, Poon M, Fallon JT, Gabel BR, Taubman MB, Koschinsky M, Harpel PC (2000) CC Chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 102(7):786–792
28. Smith EB, Cochran S (1990) Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. II. Preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis 84(2–3):173–181
29. Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M (1990) Lipoprotein(a) in the arterial wall. Eur Heart J11(Suppl E):174–183
30. Fan J, Sun H, Unoki H, Shiomi M, Watanabe T (2001) Enhanced atherosclerosis in Lp(a) WHHL transgenic rabbits. Ann N Y Acad Sci 947:362–365
31. Raghavan C, Ditchfield J, Taylor RJ, Haeney MR, Barnes PC (1993) Influence of anticardiolipin antibodies on immediate patient outcome after myocardial infarction. J Clin Pathol 46:1113–1115
32. Sletnes KE, Larsen EW, Stokland O, Wisløff F (1990) Antiphospholipid antibodies detected as anticephalin and anticardiolipin antibodies in patients with acute myocardial infarction: immunological response to myocardial necrosis? Thromb Res 59:675–680
33. Adler Y, Finkelstein Y, Zandeman-Goddard G, Blank M, Lorber M, Lorber A, Faden D, Shoenfeld Y (1995) The presence of antiphospholipid antibodies in acute myocardial infarction. Lupus 4:309–313
34. Veres K, Lakos G, Kerenyi A, Szekanecz Z, Szegedi G, Shoenfeld Y, Soltesz P (2004) Antiphospholipid antibodies in acute coronary syndrome. Lupus 13:423–427